The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.
|Articles|September 1, 2015
twitter test
Advertisement
Can circulating tumor DNA predict relapse in breast cancer?
- Dr. Muin Khoury (@DrKhouryCDC)August 30, 2015
Cool technology. Not quite ready for primetime but soon. Blood test could predict breast cancer relapse
- Hal Burstein, MD (@DrHBurstein)August 27, 2015
MT
- Michael Fisch (@fischmd)August 27, 2015
Daratumumab is safe and has encouraging activity in patients with heavily pretreated and refractory myeloma
- Muzaffar Qazilbash (@Transplant_Doc)August 26, 2015
Advertisement
Related to this article
“Cardiovascular assessment should begin when the patient is being selected for treatment, not after the toxicity emerges,” said Faisal Mehmud, MD, MRCP.
The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.